• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Dr Reddy's Lab jumps Q3 PAT soars 76% to Rs 1,247 cr
(10:03, 27 Jan 2023)
Consolidated profit before tax stood at Rs 1,634.6 crore in the quarter, up 68.36% from Rs 970.9 crore posted in Q3 FY22.

EBITDA soared 55.29% to Rs 1,965.8 crore in Q3 FY23 as against Rs 1,265.9 crore recorded in the corresponding quarter previous year. The EBITDA margin stood at 29% in Q3 FY23.

Selling, general & administrative (SG&A) expenses stood at Rs 1,798.1 crore, increased by 17% on a year on year (YoY). This increase was primarily attributable to investments in sales & marketing, annual increments, certain one-off expenses and higher forex rate. Sequentially, the SG&A expenses increased by 9% mainly due to increase in sales & marketing spends and other one-off expenses.

Research & development (R&D) expenses stood at Rs 482.1 crore. As % to revenues - Q3 FY23 was at 7.1% from 7.7% in Q2 FY23 and 7.8% in Q3 FY22. The company said that its focus on investing in R&D to build a healthy pipeline of new products across our markets including development of products in our biosimilars and generics businesses.

Other operating expense stood at Rs 73.2 crore compared to income of Rs 24 crore in Q3 FY22. Net other expense during the quarter included the loss on sale of asset at Leiden, Netherlands. Net finance expense at Rs 13.9 crore compared to income of Rs 28.9 crore in Q3 FY22.

During the quarter, revenues from Emerging Markets segment stood at Rs 1,309.7 crore, year on year growth of 14% and sequential quarter growth of 7%.

Revenues from India market stood at Rs 1,127.4 crore, year on year growth of 10% and sequential decline of 2%.

Revenues from North America market was at Rs 3,056.7 crore, year on year jump of 64% and sequential growth of 9%.

Revenues from Europe market was at Rs 430.3 crore, year on year growth of 6% and sequential rise of 2%.

Revenues from Global Generics (GG) stood at Rs 5,924.1 crore. Year on year growth of 33% and sequential quarter growth of 6% was primarily driven by new product launches, increase in volumes of base business and favorable forex movement, offset partially due to price erosion in the generic markets.

Revenues from Pharmaceutical Services and Active Ingredients (PSAI) stood at Rs 775.8 crore, year on year growth of 7% and sequential surge of 21%.

Free cash-flow stood at Rs 1,980 crore and net cash surplus for the company is at Rs 3,400 crore as on 31 December 2022.

Commenting on the results, co-chairman & MD, G V Prasad said, Our strong financial performance was supported by growth in the US and the Russia markets. We continue to strengthen our development pipeline to reach more patients globally.

Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

Powered by Capital Market - Live News

.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY)
Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355 Head Office – 114, New Delhi House, 27 Barakhamba Road, Delhi 110001 011-43606162 compliance@dbonline.in
51, Mini Market T/F Mandir Wali Gali, Yusuf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 2012002 0120-4150393 ghaziabad@dbonle.in
827, Tower B3, Spaze I Tech Park, Sector 49, Sohna Road, Gurgaon, Haryana – 122001 0124-4383584 sanjay05@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road Delhi New Delhi DL 110001- 0120-4823200 compliance@dbonline.in
DAGA BUSINESS (INTERNATIONAL) STOCK BROKERS IFSC PRIVATE LIMITED - Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, GIFT SEZ, Gandhinagar,Gujarat 382355 - 0120-4823200 compliance@dbonline.in
Investor Grievances Email ID: investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"